Overview

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Status:
Active, not recruiting

Trial end date:
2022-02-23

Target enrollment:

Participant gender:

Summary

This study will assess the safety, tolerability, and pharmacokinetics of AZD1775 (adavosertib) given orally in combination with intravenous MEDI4736 (durvalumab). Secondly, the immunogenicity, pharmacodynamics, and preliminary anti-tumour activity will be determined in patients with refractory solid tumours.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Adavosertib
Antibodies, Monoclonal
Durvalumab